These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 34790170)

  • 21. Sodium glucose cotransporter 2 and the diabetic kidney.
    Komala MG; Panchapakesan U; Pollock C; Mather A
    Curr Opin Nephrol Hypertens; 2013 Jan; 22(1):113-9. PubMed ID: 23042029
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel therapeutic agents for the treatment of diabetic kidney disease.
    Hartman RE; Rao PSS; Churchwell MD; Lewis SJ
    Expert Opin Investig Drugs; 2020 Nov; 29(11):1277-1293. PubMed ID: 32799584
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The roles of sodium-glucose cotransporter 2 inhibitors in preventing kidney injury in diabetes.
    Jaikumkao K; Pongchaidecha A; Chatsudthipong V; Chattipakorn SC; Chattipakorn N; Lungkaphin A
    Biomed Pharmacother; 2017 Oct; 94():176-187. PubMed ID: 28759755
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of Diabetic Kidney Disease: Current and Future.
    Yamazaki T; Mimura I; Tanaka T; Nangaku M
    Diabetes Metab J; 2021 Jan; 45(1):11-26. PubMed ID: 33508907
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation.
    Tuttle KR; Brosius FC; Cavender MA; Fioretto P; Fowler KJ; Heerspink HJL; Manley T; McGuire DK; Molitch ME; Mottl AK; Perreault L; Rosas SE; Rossing P; Sola L; Vallon V; Wanner C; Perkovic V
    Am J Kidney Dis; 2021 Jan; 77(1):94-109. PubMed ID: 33121838
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety profile of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease.
    Scheen AJ
    Expert Opin Drug Saf; 2020 Mar; 19(3):243-256. PubMed ID: 32083962
    [No Abstract]   [Full Text] [Related]  

  • 27. The Potential Role of SGLT2 Inhibitors in the Treatment of Type 1 Diabetes Mellitus.
    Fattah H; Vallon V
    Drugs; 2018 May; 78(7):717-726. PubMed ID: 29663292
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SGLT2 Inhibitors: Glucotoxicity and Tumorigenesis Downstream the Renal Proximal Tubule?
    Bertinat R; Nualart F; Yáñez AJ
    J Cell Physiol; 2016 Aug; 231(8):1635-7. PubMed ID: 26661279
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SGLT2 Inhibitors: Nephroprotective Efficacy and Side Effects.
    Garofalo C; Borrelli S; Liberti ME; Andreucci M; Conte G; Minutolo R; Provenzano M; De Nicola L
    Medicina (Kaunas); 2019 Jun; 55(6):. PubMed ID: 31212638
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inflammation and Oxidative Stress in Diabetic Kidney Disease: The Targets for SGLT2 Inhibitors and GLP-1 Receptor Agonists.
    Winiarska A; Knysak M; Nabrdalik K; Gumprecht J; Stompór T
    Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639160
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Techniques to Assess the Effect of Sodium-Glucose Cotransporter 2 Inhibitors on Blood Volume in Patients with Diabetic Kidney Disease.
    Vinje V; Bomholt T; Rossing P; Lundby C; Oturai P; Hornum M
    Nephron; 2024; 148(3):137-142. PubMed ID: 37812920
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of sodium-glucose cotransporter 2 inhibition to mitigate diabetic kidney disease risk in type 1 diabetes.
    van Raalte DH; Bjornstad P
    Nephrol Dial Transplant; 2020 Jan; 35(Suppl 1):i24-i32. PubMed ID: 32003832
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of SGLT2 inhibition in human kidney proximal tubular cells--renoprotection in diabetic nephropathy?
    Panchapakesan U; Pegg K; Gross S; Komala MG; Mudaliar H; Forbes J; Pollock C; Mather A
    PLoS One; 2013; 8(2):e54442. PubMed ID: 23390498
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mechanisms Leading to Differential Hypoxia-Inducible Factor Signaling in the Diabetic Kidney: Modulation by SGLT2 Inhibitors and Hypoxia Mimetics.
    Packer M
    Am J Kidney Dis; 2021 Feb; 77(2):280-286. PubMed ID: 32711072
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pleiotropic Effects of Sodium-Glucose Cotransporter-2 Inhibitors: Renoprotective Mechanisms beyond Glycemic Control.
    Takata T; Isomoto H
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33922132
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Potential Mechanism of Cardio-Renal Protection with Sodium-Glucose Cotransporter 2 Inhibitors: Amelioration of Renal Congestion.
    Kuriyama S
    Kidney Blood Press Res; 2019; 44(4):449-456. PubMed ID: 31291624
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SGLT2 inhibitors improve kidney function and morphology by regulating renal metabolic reprogramming in mice with diabetic kidney disease.
    Lu YP; Zhang ZY; Wu HW; Fang LJ; Hu B; Tang C; Zhang YQ; Yin L; Tang DE; Zheng ZH; Zhu T; Dai Y
    J Transl Med; 2022 Sep; 20(1):420. PubMed ID: 36104729
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interplay of adenosine monophosphate-activated protein kinase/sirtuin-1 activation and sodium influx inhibition mediates the renal benefits of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes: A novel conceptual framework.
    Packer M
    Diabetes Obes Metab; 2020 May; 22(5):734-742. PubMed ID: 31916329
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SGLT-2 inhibitors in Diabetic Kidney Disease: What Lies Behind their Renoprotective Properties?
    Georgianos PI; Divani M; Eleftheriadis T; Mertens PR; Liakopoulos V
    Curr Med Chem; 2019; 26(29):5564-5578. PubMed ID: 29792136
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Glucose Lowering Efficacy and Pleiotropic Effects of Sodium-Glucose Cotransporter 2 Inhibitors.
    Kuchay MS; Farooqui KJ; Mishra SK; Mithal A
    Adv Exp Med Biol; 2021; 1307():213-230. PubMed ID: 32006266
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.